Insmed (NASDAQ:INSM) will be posting its quarterly earnings results before the market opens on Wednesday, February 21st. Analysts expect Insmed to post earnings of ($0.68) per share for the quarter.
Shares of Insmed (NASDAQ INSM) opened at $24.23 on Tuesday. Insmed has a one year low of $11.49 and a one year high of $33.94. The firm has a market cap of $1,860.00, a PE ratio of -7.77 and a beta of 1.09. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13.
A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Insmed from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. BidaskClub raised shares of Insmed from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Cowen reissued a “buy” rating and set a $54.00 price target on shares of Insmed in a research report on Friday, November 3rd. Finally, Credit Suisse Group initiated coverage on shares of Insmed in a research report on Wednesday, January 17th. They set a “neutral” rating and a $31.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $36.67.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.